Correlación genotipo-fenotipo de pacientes con esclerosis tuberosa de la costa caribe colombiana

datacite.rightshttp://purl.org/coar/access_right/c_16ecspa
dc.contributor.advisorLozano Solano, Dayan
dc.contributor.advisorOrtega Ríos, Rita
dc.contributor.authorCaraballo Payares, Aldo Tomás
dc.date.accessioned2023-12-14T14:54:11Z
dc.date.available2023-12-14T14:54:11Z
dc.date.issued2023
dc.description.abstractIntroducción: El complejo esclerosis tuberosa (CET), es una facomatosis dentro del espectro de las enfermedades huérfanas, que se caracteriza por el crecimiento de hamartomas. La morbimortalidad que esta enfermedad conlleva durante toda la vida del paciente le condiciona una gran carga para él, su familia, la comunidad y el sistema de salud. Objetivo: Correlacionar el genotipo-fenotipo de pacientes con CET que consultaron a un hospital neurológico de Cartagena desde 2011 a 2021. Metodología: Se hizo la prueba molecular por NGS de los genes TSC1 y TSC2 a 12 pacientes con diagnóstico clínico definitivo y se obtuvo un resultado positivo en el 83,3%. El rango de edad fue de los 4 a 37 años. No hubo predominio de un género. El inicio de síntomas fue antes del año de edad en el 50% de los casos. No tenían antecedentes familiares. Las manifestaciones neurológicas y dermatológicas fueron las más frecuentes. El gen TSC2 fue el más afectado (66,6%). Conclusión: Siendo una muestra pequeña, no se pudo realizar la correlación. Este el primer estudio colombiano que intenta describirla.spa
dc.description.abstractIntroduction: Tuberous sclerosis complex (TSC) is a phakomatosis within the spectrum of orphan diseases, which is characterized by the growth of hamartomas. The morbidity and mortality that this disease entails throughout the patient's life places a great burden on him, his family, the community and the health system. Objective: To correlate the genotype-phenotype of patients with TSC who consulted a neurological hospital in Cartagena from 2011 to 2021. Methodology: NGS molecular testing of the TSC1 and TSC2 genes was performed on 12 patients with a definitive clinical diagnosis and a positive result was obtained. in 83.3%. The age range was from 4 to 37 years. There was no predominance of one gender. The onset of symptoms was before one year of age in 50% of the cases. They had no family history. Neurological and dermatological manifestations were the most frequent. The TSC2 gene was the most affected (66.6%). Conclusion: Being a small sample, the correlation could not be made. This is the first Colombian study that attempts to describe it.eng
dc.format.mimetypepdfspa
dc.identifier.urihttps://hdl.handle.net/20.500.12442/13657
dc.language.isospaspa
dc.publisherEdiciones Universidad Simón Bolívarspa
dc.publisherFacultad de Ciencias Básicas y Biomédicasspa
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.rights.accessrightsinfo:eu-repo/semantics/restrictedAccessspa
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectComplejo de esclerosis tuberosaspa
dc.subjectGenotipospa
dc.subjectFenotipospa
dc.subjectCorrelaciónspa
dc.subjectTuberous sclerosis complexeng
dc.subjectGenotypeeng
dc.subjectPhenotypeeng
dc.subjectCorrelationeng
dc.titleCorrelación genotipo-fenotipo de pacientes con esclerosis tuberosa de la costa caribe colombianaspa
dc.type.driverinfo:eu-repo/semantics/masterThesisspa
dc.type.spaTrabajo de grado másterspa
dcterms.referencesWilbur C, Sanguansermsri C, Chable H, Anghelina M, Peinhof S, Anderson K, Steinbok P, Singhal A, Datta A, Connolly MB. Manifestations of Tuberous Sclerosis Complex: The Experience of a Provincial Clinic. Can J Neurol Sci. 2017 Jan; 44(1):35-43. doi: 10.1017/cjn.2016.311. PMID: 28004629.eng
dcterms.referencesHodgson N, Kinori M, Goldbaum MH, Robbins SL. Ophthalmic manifestations of tuberous sclerosis: a review. Clin Exp Ophthalmol. 2017 Jan; 45(1):81-86. doi: 10.1111/ceo.12806. Epub 2016 Sep 15. PMID: 27447981.eng
dcterms.referencesCammarata-Scalisi F, Lacruz-Rengel M, Stock F, Vidales C, Callea M. Aspectos clínicos y genéticos del complejo esclerosis tuberosa. Arch Venez Puer Ped. 2017; Vol 80 (1): 27-33. Disponible en: http://ve.scielo.org/scielo.php?script=sci_arttext&pid=S0004-06492017000100007&lng=es.spa
dcterms.referencesMonteiro T, Garrido C, Pina S, Chorão R, Carrilho I, Figueiroa S, et al. Esclerosis tuberosa: caracterización clínica e intento de correlación fenotipo/genotipo. An Pediatr (Engl Ed). 2014; 81(5). DOI: 10.1016/j.anpedi.2014.03.022spa
dcterms.referencesSahin M, Henske EP, Manning BD, Ess KC, Bissler JJ, Klann E, et al. Advances and future directions for tuberous sclerosis complex research: Recommendations from the 2015 strategic planning conference. Vol. 60, Pediatric Neurology. 2016. doi: 10.1016/j.pediatrneurol.2016.03.015. Epub 2016 Apr 2.eng
dcterms.referencesTorres V, Contreras GA, Serrano N, Páez MC, Guzmán MC. Complejo de la esclerosis tuberosa, revisión de tema y presentación de caso. Rev asoc colomb dermatol 2011; 19 (1):76-81. Disponible en: https://revista.asocolderma.org.co/index.php/asocolderma/article/view/390spa
dcterms.referencesOrlova KA, Crino PB. The tuberous sclerosis complex. Vol. 1184, Annals of the New York Academy of Sciences. Blackwell Publishing Inc.; 2010. p. 87–105. doi: 10.1111/j.1749-6632.2009.05117.x.eng
dcterms.referencesCuratolo P, Bombardieri R, Jozwiak S. Tuberous sclerosis. Lancet. 2008; 372:657–68. doi: 10.1016/S0140-6736(08)61279-9.eng
dcterms.referencesRubilar C, López F, Troncoso M, Barrios A, Herrera L. Estudio clínico genético en pacientes con complejo de esclerosis tuberosa. Rev Chil Pediatr. 2017; 88(1). http://dx.doi.org/10.1016/j.rchipe.2016.08.003spa
dcterms.referencesCrino P, Nathason K, Petri E. The tuberous sclerosis complex. N Engl J Med. 2006 Sep 28; 355(13):1345–56. DOI: 10.1056/NEJMra055323eng
dcterms.referencesAl-Saleem T, Wessner LL, Scheithauer BW, Patterson K, Roach ES, Dreyer SJ, et al. Malignant Tumors of the Kidney, Brain, and Soft Tissues in Children and Young Adults with the Tuberous Sclerosis Complex. Cancer 1998 Nov 15; 83 (10):2208-16. disponible en: https://acsjournals.onlinelibrary.wiley.com/doi/10.1002/eng
dcterms.referencesSwiton K, Kotulska K, Janusz-Kaminska A, Zmorzynska J, Jaworski J. Molecular neurobiology of mTOR. Vol. 341, Neuroscience. Elsevier Ltd; 2017. p. 112–53. DOI: 10.1016/j.neuroscience.2016.11.017eng
dcterms.referencesHernandez O, Way S, McKenna J, Gambello MJ. Generation of a conditional disruption of the Tsc2 gene. Genesis. 2007; 45(2). DOI: 10.1002/dvg.20271eng
dcterms.referencesChipaux M, Chiron C, Touraine R, Ouss L, Dulac O, Nabbout R. Tuberous sclerosis: current practices and news. Epilepsies. 2009 Jan; 21(1):34–40. 10.1684/epi.2009.0220eng
dcterms.referencesDabora SL, Kwiatkowski DJ, Franz DN, Roberts PS, Nieto A, Chung J, et al. Mutational analysis in a cohort of 224 tuberous sclerosis patients indicates increased severity of TSC2, compared with TSC1, disease in multiple organs. Am J Hum Genet. 2001; 68(1). doi: 10.1086/316951.eng
dcterms.referencesRoach ES. Applying the Lessons of Tuberous Sclerosis: The 2015 Hower Award Lecture. Vol. 63, Pediatric Neurology. 2016. DOI: 10.1016/j.pediatrneurol.2016.07.003eng
dcterms.referencesMacaya A, Torra R. Recommendations for the multidisciplinary management of tuberous sclerosis complex. Med Clin (Barc). 2016 May; 147(5):211–6. DOI: 10.1016/j.medcli.2016.04.004eng
dcterms.referencesLacruz-Rengel MA, Jiménez MG, Cammarata-Scalisi F. Epilepsia en niños con esclerosis tuberosa: experiencia en el instituto autónomo hospital universitario de los Andes. Arch venez pueric pediatr. 2011; 74(3). Disponible en: http://ve.scielo.org/scielo.php?script=sci_arttext&pid=S0004-06492011000300006&lng=es.spa
dcterms.referencesNúñez E, Bonilla Y, Valera D. Actualización de métodos diagnósticos en el Complejo de Esclerosis Tuberosa. Revista Mexicana de Neurociencia. 2016; 17(4). https://www.medigraphic.com/cgi-bin/new/resumen.cgi?IDARTICULO=69100spa
dcterms.referencesMedina-Malo C, Carreño O, Vélez A, Lizcano LA, Ortíz LD, Becerra H, et al. Complejo esclerosis tuberosa. Bogotá; 2012 Mar; 28 (1):11-23. Disponible en: https://www.researchgate.net/publication/262449207_Tuberous_sclerosis_complexspa
dcterms.referencesLópez MF. Complejo esclerosis tuberosa: aspectos moleculares y genéticos. Actualización. Revista Chilena de Epilepsia. 2012; 12(1):105–10.spa
dcterms.referencesQuesada JF, Alonso MC. Complejo esclerosis tuberosa, caso clínico. Ed Cont Lab Clín. Madrid, 2016; 27: 25-39. Disponible en: https://www.seqc.es/download/tema/9/3875/9175045/1912513/cms/tema-3-complejo-esclerosis-tuberosa.pdf/spa
dcterms.referencesNorthrup H, Krueger DA, Roberds S, Smith K, Sampson J, Korf B, et al. Tuberous sclerosis complex diagnostic criteria update: Recommendations of the 2012 international tuberous sclerosis complex consensus conference. Pediatr Neurol. 2013; 49(4). DOI: 10.1016/j.pediatrneurol.2013.08.001eng
dcterms.referencesBoronat S. Sábado C. Vendrell T. Complejo Esclerosis Tuberosa. Grupo de Trabajo sobre Cáncer en Síndromes Genéticas Polimalformativos (2015 GT-CSGP). Barcelona – España. Disponible en: https://www.orpha.es/data/patho/Cpg/es/ComplejoEsclerosisTuberosa_ES-es_CPG_ORPHA805.pdfspa
dcterms.referencesFalsafi P, Taghavi-Zenouz A, Khorshidi-Khiyavi R, Nezami N, Mehrdad &, Estiar A, et al. A Case of Tuberous Sclerosis Without Multiorgan Involvement. Glob J Health Sci. 2015; 7(5). doi: 10.5539/gjhs.v7n5p124eng
dcterms.referencesSorokin I, Cecilia Remes Lenicov M, Pereira V, Raffaeli R, Nave G, Pereyra Ramos G, et al. Complejo Esclerosis Tuberosa: diagnóstico en la edad adulta. Vol. 65, Arch. Argent. Dermatol. Buenos Aires; 2015. Disponible en: http://www.archivosdermato.org.ar/wp-content/uploads/2019/10/104Sorokin-Complejo-esclerosis-tuberosa.pdfspa
dcterms.referencesHenske EP, Józwiak S, Kingswood JC, Sampson JR, Thiele EA. Tuberous sclerosis complex. Nat Rev Dis Primers. 2016; 2:16035. doi: 10.1038/nrdp.2016.35.eng
dcterms.referencesMorrison PJ, Donnelly DE. How common is tuberous sclerosis complex? . Br J Dermatol. 2016 Jun; 174(6): 1184–5. https://doi.org/10.1111/bjd.14592eng
dcterms.referencesCaban C, Khan N, Hasbani DM, Crino PB. Genetics of tuberous sclerosis complex: Implications for clinical practice. Appl Clin Genet 2016 Dec 21; 10:1-8. DOI: 10.2147/TACG.S90262eng
dcterms.referencesJozwiak J, Jozwiak S, Wlodarski P. Possible mechanisms of disease development in tuberous sclerosis. Lancet Oncol. 2008 Jan; 9(1): 73-9. DOI: 10.1016/S1470-2045(07)70411-4eng
dcterms.referencesBrook-Carter PT, Peral B, Ward CJ, Thompson P, Hughes J, Maheshwar MM. Deletion of the TSC2 and PKD1 genes associated with severe infantile polycystic kidney disease--a contiguous gene syndrome. Nat Genet. 1994 Dec; 8(4): 328–32. DOI: 10.1038/ng1294-328eng
dcterms.referencesSampson JR, Maheshwar MM, Aspinwall R, Thompson P, Cheadle JP, Ravine D, et al. Renal cystic disease in tuberous sclerosis: Role of the polycystic kidney disease 1 gene. Am J Hum Genet. 1997; 61(4). DOI: 10.1086/514888eng
dcterms.referencesNapolioni V, Curatolo P. Genetics and Molecular Biology of Tuberous Sclerosis Complex. Curr Genomics. 2008; 9(7). DOI: 10.2174/138920208786241243eng
dcterms.referencesMozaffari M, Hoogeveen-Westerveld M, Kwiatkowski D, Sampson J, Ekong R, Povey S, et al. Identification of a region required for TSC1 stability by functional analysis of TSC1 missense mutations found in individuals with tuberous sclerosis complex. BMC Med Genet. 2009; 10. doi: 10.1186/1471-2350-10-88eng
dcterms.referencesOsborne JP, Merrifield J, O’Callaghan FJK. Tuberous sclerosis - What’s new? Vol. 93, Archives of Disease in Childhood. 2008. p. 728–31. DOI:10.1136/adc.2006.094938eng
dcterms.referencesCrino PB. The pathophysiology of tuberous sclerosis complex. In: Epilepsia. 2010 Feb; 51 Suppl 1: 27-9. https://doi.org/10.1111/j.1528-1167.2009.02438.xeng
dcterms.referencesMeng XF, Yu JT, Song JH, Chi S, Tan L. Role of the mTOR signaling pathway in epilepsy. J Neurol Sci. 2013 Sep; 332(1–2): 4–15. DOI: 10.1016/j.jns.2013.05.029eng
dcterms.referencesAu KS, Williams AT, Roach ES, Batchelor L, Sparagana SP, Delgado MR, et al. Genotype/phenotype correlation in 325 individuals referred for a diagnosis of tuberous sclerosis complex in the United States. Genetics in Medicine. 2007 Feb; 9(2): 88–100. https://doi.org/10.1097/GIM.0b013e31803068c7eng
dcterms.referencesBarboza M, Bermúdez I, Diaz D. Trastorno generalizado del desarrollo y esclerosis tuberosa, Presentación de caso clínico. Acta Neurol Colomb. 2014 Oct; 30(4): 331–6. Disponible en: https://pesquisa.bvsalud.org/portal/resource/pt/biblio-949568spa
dcterms.referencesCuri M, Cardoso C, Ikuta C, Koga D, Zardetto C. Tuberous Sclerosis: A Case Report with Oral Manifestation. International journal of odontostomatology. 2014; 8(2). http://dx.doi.org/10.4067/S0718-381X2014000200006eng
dcterms.referencesGarcia NG, de Carli ML, Oliveira DT, Soares CT, Ribeiro Júnior NV, Sperandio FF, et al. Tuberous Sclerosis with Severe Cutaneous Manifestation and Multiples Facial Angiofibromas. Head Neck Pathol. 2016; 10(4). DOI: 10.1007/s12105-016-0723-8eng
dcterms.referencesSodhi S, Dang R, Brar G. Tuberous sclerosis with oral manifestations: A rare case report. Int J Appl Basic Med Res. 2016; 6(1). doi: 10.4103/2229-516X.174018eng
dcterms.referencesDocampo J, Cabrini M, Bruno C, Morales YC. Esclerosis tuberosa: Evaluación de las lesiones intracraneanas. Revista Argentina de Radiologia. 2013; 77(4). Disponible en: http://www.scielo.org.ar/scielo.php?script=sci_arttext&pid=S1852-99922013000400004&lng=es.spa
dcterms.referencesSalgado AG, Belaunzarán A, Gandini A. Esclerosis tuberosa: hallazgos radiológicos en SNC y riñones: A propósito de un caso. Revista del Hospital Privado de Comunidad. Córdoba, 2013; 16 (1): 25-8. Disponible en: https://hpc.org.ar/wp-content/uploads/905-6-Salgado1.pdfspa
dcterms.referencesKrueger DA, Wilfong AA, Mays M, Talley CM, Agricola K, Tudor C, et al. Long-term treatment of epilepsy with everolimus in tuberous sclerosis. Neurology. 2016; 87(23). DOI: 10.1212/WNL.0000000000003400eng
dcterms.referencesJeong A. Tuberous Sclerosis Complex: A Roadmap for Future Research. Pediatr Neurol Briefs. 2016; 30(7). doi: 10.15844/pedneurbriefs-30-7-1eng
dcterms.referencesYates JRW, MacLean C, Higgins JNP, Humphrey A, le Maréchal K, Clifford M, et al. The tuberous sclerosis 2000 study: Presentation initial assessments and implications for diagnosis and management. Arch Dis Child. 2011; 96(11). DOI: 10.1136/adc.2011.211995eng
dcterms.referencesPadilla-Vázquez F, Mendizábal-Guerra R, Ayala AA, et al. Esclerosis tuberosa. Arch Neurocien. 2012; 17(2):132-137. Disponible en: https://www.medigraphic.com/pdfs/arcneu/ane-2012/ane122i.pdfspa
dcterms.referencesWarncke JC, Brodie KE, Grantham EC, Catarinicchia SP, Tong S, Kondo KL, et al. Pediatric Renal Angiomyolipomas in Tuberous Sclerosis Complex. Journal of Urology. 2017; 197(2). DOI: 10.1016/j.juro.2016.09.082eng
dcterms.referencesKingswood JC, Bissler JJ, Budde K, Hulbert J, Guay-Woodford L, Sampson JR, et al. Review of the Tuberous Sclerosis Renal Guidelines from the 2012 Consensus Conference: Current Data and Future Study. Nephron 2016; 134(2):51-58. DOI: 10.1159/000448293eng
dcterms.referencesJohnson SR, Taveira-DaSilva AM, Moss J. Lymphangioleiomyomatosis. Clin Chest Med. 2016 Sep 1; 37(3): 389–403. DOI: 10.1016/j.ccm.2016.04.002eng
dcterms.referencesKoc G, Sugimoto S, Kuperman R, Kammen BF, Karakas SP. Pancreatic tumors in children and young adults with tuberous sclerosis complex. Pediatr Radiol. 2017; 47(1). DOI: 10.1007/s00247-016-3701-0eng
dcterms.referencesKingswood JC, Crawford P, Johnson SR, Sampson JR, Shepherd C, Demuth D, et al. The economic burden of tuberous sclerosis complex in the UK: A retrospective cohort study in the Clinical Practice Research Datalink. J Med Econ 2016; 19(11): 1087–98. DOI: 10.1080/13696998.2016.1199432eng
dcterms.referencesSancak O, Nellist M, Goedbloed M, Elfferich P, Wouters C, Maat-Kievit A, et al. Mutational analysis of the TSC1 and TSC2 genes in a diagnostic setting: Genotype-phenotype correlations and comparison of diagnostic DNA techniques in tuberous sclerosis complex. European Journal of Human Genetics. 2005; 13(6). DOI: 10.1038/sj.ejhg.5201402eng
dcterms.referencesRosset C, Vairo F, Bandeira IC, Correia RL, de Goes FV, da Silva RTB, et al. Molecular analysis of TSC1 and TSC2 genes and phenotypic correlations in Brazilian families with tuberous sclerosis. PLoS One. 2017; 12(10). doi: 10.1371/journal.pone.0185713. PMID: 28968464; PMCID: PMC5624610eng
dcterms.referencesRuiz-Falcó Rojas ML. Actualización terapéutica en el complejo esclerosis tuberosa: el papel de los inhibidores de la vía mTOR. Rev Neurol. 2012; 54(S03). 10.33588/rn.54S03.2012244.spa
dcterms.referencesJeong A, Wong M. mTOR Inhibitors in Children: Current Indications and Future Directions in Neurology. Curr Neurol Neurosci Rep 2016 Dec; 16(12): 102. DOI: 10.1007/s11910-016-0708-8eng
dcterms.referencesCapal JK, Franz DN. Profile of everolimus in the treatment of tuberous sclerosis complex: An evidence-based review of its place in therapy. Neuropsychiatr Dis Treat 2016 Aug 25; 12: 2165-72. DOI: 10.2147/NDT.S91248eng
dcterms.referencesvan Karnebeek CDM, Bowden K, Berry-Kravis E. Treatment of Neurogenetic Developmental Conditions: From 2016 into the Future. Pediatric Neurology 2016; 65: 1-13. DOI: 10.1016/j.pediatrneurol.2016.07.010eng
dcterms.referencesDing Y, Wang J, Zhou S, Zhou Y, Zhang L, Yu L, et al. Genotype and Phenotype Analysis of Chinese Children With Tuberous Sclerosis Complex: A Pediatric Cohort Study. Front Genet. 2020 Mar 10; 11. doi: 10.3389/fgene.2020.00204.eng
dcterms.referencesGeorgieva B, Koleva M, Todorov T, Bojinova V, Deneva D, Glushkova M, et al. Molecular-genetic characteristics and genotype-phenotype correlations in Bulgarian patients with tuberous sclerosis complex. Acta Medica Bulgarica. 2021; 48(2). https://doi.org/10.2478/amb-2021-0020eng
dcterms.referencesRichards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and guidelines for the interpretation of sequence variants: A joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genetics in Medicine. 2015 May 8; 17(5): 405–24. https://doi.org/10.1038/gim.2015.30eng
dcterms.referencesvan Slegtenhorst M, Verhoef S, Tempelaars A, Bakker L, Wang Q, Wessels M, et al. Mutational spectrum of the TSC1 gene in a cohort of 225 tuberous sclerosis complex patients: No evidence for genotype-phenotype correlation. J Med Genet. 1999; 36(4). https://pubmed.ncbi.nlm.nih.gov/10227394/eng
dcterms.referencesJones AC, Shyamsundar MM, Thomas MW, Maynard J, Idziaszczyk S, Tomkins S, et al. Comprehensive mutation analysis of TSC1 and TSC2 - And phenotypic correlations in 150 families with tuberous sclerosis. Am J Hum Genet. 1999; 64(5). DOI: 10.1086/302381eng
dcterms.referencesAlsowat D, Whitney R, Hewson S, Jain P, Chan V, Kabir N, et al. The Phenotypic Spectrum of Tuberous Sclerosis Complex: A Canadian Cohort. Child Neurol Open. 2021; 8. doi:10.1177/2329048X211012817eng
dcterms.referencesMuto Y, Sasaki H, Sumitomo M, Inagaki H, Kato M, Kato T, et al. Genotype-phenotype correlation of renal lesions in the tuberous sclerosis complex. Hum Genome Var. 2022; 9(1). https://doi.org/10.1038/s41439-022-00181-1.eng
dcterms.referencesLuo, C., Zhang, Y., Zhang, Ys. et al. Renal phenotypes correlate with genotypes in unrelated individuals with tuberous sclerosis complex in China. Orphanet J Rare Dis 2022; 17, 288. https://doi.org/10.1186/s13023-022-02443-1eng
dcterms.referencesTyburczy ME, Dies KA, Glass J, Camposano S, Chekaluk Y, Thorner AR, et al. Mosaic and Intronic Mutations in TSC1/TSC2 Explain the Majority of TSC Patients with No Mutation Identified by Conventional Testing. PLoS Genet. 2015 Nov 1; 11(11). DOI: 10.1371/journal.pgen.1005637eng
dcterms.referencesTreichel AM, Hamieh L, Nathan NR, Tyburczy ME, Wang J an, Oyerinde O, et al. Phenotypic distinctions between mosaic forms of tuberous sclerosis complex. Genetics in Medicine 2019 Nov; 21(11): 2594-2604. DOI: 10.1038/s41436-019-0520-3eng
dcterms.referencesGiannikou K, Lasseter KD, Grevelink JM, Tyburczy ME, Dies KA, Zhu Z, et al. Low-level mosaicism in tuberous sclerosis complex: prevalence, clinical features, and risk of disease transmission. Genetics in Medicine 2019 Nov; 21(11): 2639-2643. DOI: 10.1038/s41436-019-0562-6eng
dcterms.referencesDibble CC, Elis W, Menon S, Qin W, Klekota J, Asara JM, et al. TBC1D7 Is a Third Subunit of the TSC1-TSC2 Complex Upstream of mTORC1. Mol Cell 2012 Aug; 47(4): 535–46. DOI: 10.1016/j.molcel.2012.06.009eng
dcterms.referencesJones AC, Daniells CE, Snell RG, Tachataki M, Idziaszczyk SA, Krawczak M, et al. Molecular genetic and phenotypic analysis reveals differences between TSC1 and TSC2 associated familial and sporadic tuberous sclerosis. Hum Mol Genet 1997; 6(12). DOI: 10.1093/hmg/6.12.2155eng
dcterms.referencesJansen FE, Vincken KL, Algra A, Anbeek P, Braams O, Nellist M, et al. Cognitive impairment in tuberous sclerosis complex is a multifactorial condition. Neurology 2008; 70(12). DOI: 10.1212/01.wnl.0000280579.04974.c0.eng
oaire.versioninfo:eu-repo/semantics/acceptedVersionspa
sb.programaMaestría en Genéticaspa
sb.sedeSede Barranquillaspa

Archivos

Bloque original
Mostrando 1 - 2 de 2
Cargando...
Miniatura
Nombre:
PDF_Resumen
Tamaño:
217.23 KB
Formato:
Adobe Portable Document Format
No hay miniatura disponible
Nombre:
PDF.pdf
Tamaño:
1.94 MB
Formato:
Adobe Portable Document Format

Colecciones